GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 167 [US11046691] | GSK-4362676 | GSK4362676 | IDE-397
Compound class:
Synthetic organic
Comment: IDE397 is a methionine adenosyltransferase 2A (MAT2A) inhibitor [1-3]. It was designed to target the MAT2A-SAM axis and induce synthetic lethal effects in MTAP-deleted tumours.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| IDE397 was progressed as a clinical candidate for the treatment of MTAP-deleted solid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase 1 Interventional | IDEAYA Biosciences | ||
| NCT05975073 | A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | Phase 1/Phase 2 Interventional | Amgen | ||
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase 1 Interventional | IDEAYA Biosciences | ||